Related Experiment Video
Updated: Jan 12, 2026
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
1.1K
Sarcopenia and MASLD: novel insights and the future
Chang-Hai Liu1,2, Qing-Min Zeng1,2, Won Kim3,4
1Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Nature Reviews. Endocrinology
|November 5, 2025
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia often coexist, driven by metabolic syndrome. Addressing metabolic factors is key for managing both conditions and improving patient outcomes.
Area of Science:
- Hepatology and Metabolic Health
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally, linked to obesity.
- MASLD frequently coexists with sarcopenia, characterized by age-related muscle mass and function loss.
Purpose of the Study:
- To review the epidemiological link between MASLD and sarcopenia.
- To explore the role of metabolic syndrome in MASLD and sarcopenia development and progression.
- To summarize current and emerging treatment strategies.
Main Methods:
- Literature review focusing on epidemiological data and mechanistic insights.
- Analysis of the impact of metabolic syndrome components on MASLD and sarcopenia.
- Synthesis of current treatment approaches and future research directions.
Main Results:
- Metabolic syndrome significantly influences the risk and progression of both MASLD and sarcopenia through various mechanisms.
- Effective management requires integrating the five metabolic risk factors of metabolic syndrome into clinical practice.
Conclusions:
- Integrated management of MASLD and sarcopenia, considering metabolic syndrome, is crucial.
- Further research into underlying mechanisms and the development of standardized definitions and personalized treatments are needed for improved patient outcomes.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K